Fibroblast growth factor 2 and the protease activity of tumor

J. A M Maier, M. Mariotti, L. Meneghini, U. Cavallaro, Z. Wu, G. Massazza, D. Campioni, a. Corallini, G. Barbanti-Brodano, M. R. Soria

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In BK virus (BKV)/tat transgenic mice, the relatively low incidence and long latency period of tumors indicate that the BKV/tat transgene is not sufficient for the expression of a complete oncogenic phenotype. Since angiogenesis and the production of proteases are critical for tumor growth, we evaluated the expression of two potent angiogenic molecules, fibroblast growth factor type 2 (FGF-2), and hepatocyte growth factor (HGF), and of the fibrinolytic system in cell lines isolated from tumors of different histotypes developed by BKV/tat transgenic mice. Here we show that the overexpression of HGF is a unique feature of spindle cells derived from murine Kaposi's sarcoma-like lesions, whereas FGF-2 is detectable in all the cell lines tested. Interestingly, FGF-2 is secreted only by adenocarcinoma-derived T53 cells that show a fully transformed phenotype in vitro. In addition, T53 cells synthesize larger amounts of urokinase-type plasminogen activator (uPA) than the other cell lines studied. This is due to the secretion of FGF-2 and not to the presence of extracellular Tat. We conclude that the high levels of expression of uPA and its receptor, and the very low levels of plasminogen activator inhibitor type 1, may contribute to the tumorigenic phenotype of T53 cells.

Original languageEnglish
Pages (from-to)309-315
Number of pages7
JournalFibrinolysis
Volume10
Issue number5-6
DOIs
Publication statusPublished - 1996

Fingerprint

Fibroblast Growth Factor 2
BK Virus
Peptide Hydrolases
Hepatocyte Growth Factor
Phenotype
Transgenic Mice
Neoplasms
Urokinase Plasminogen Activator Receptors
Cell Line
Kaposi's Sarcoma
Plasminogen Activator Inhibitor 1
Urokinase-Type Plasminogen Activator
Tumor Cell Line
Transgenes
Adenocarcinoma
Incidence
Growth

ASJC Scopus subject areas

  • Hematology

Cite this

Maier, J. A. M., Mariotti, M., Meneghini, L., Cavallaro, U., Wu, Z., Massazza, G., ... Soria, M. R. (1996). Fibroblast growth factor 2 and the protease activity of tumor. Fibrinolysis, 10(5-6), 309-315. https://doi.org/10.1016/S0268-9499(96)80012-9

Fibroblast growth factor 2 and the protease activity of tumor. / Maier, J. A M; Mariotti, M.; Meneghini, L.; Cavallaro, U.; Wu, Z.; Massazza, G.; Campioni, D.; Corallini, a.; Barbanti-Brodano, G.; Soria, M. R.

In: Fibrinolysis, Vol. 10, No. 5-6, 1996, p. 309-315.

Research output: Contribution to journalArticle

Maier, JAM, Mariotti, M, Meneghini, L, Cavallaro, U, Wu, Z, Massazza, G, Campioni, D, Corallini, A, Barbanti-Brodano, G & Soria, MR 1996, 'Fibroblast growth factor 2 and the protease activity of tumor', Fibrinolysis, vol. 10, no. 5-6, pp. 309-315. https://doi.org/10.1016/S0268-9499(96)80012-9
Maier, J. A M ; Mariotti, M. ; Meneghini, L. ; Cavallaro, U. ; Wu, Z. ; Massazza, G. ; Campioni, D. ; Corallini, a. ; Barbanti-Brodano, G. ; Soria, M. R. / Fibroblast growth factor 2 and the protease activity of tumor. In: Fibrinolysis. 1996 ; Vol. 10, No. 5-6. pp. 309-315.
@article{0606d93da2ce41ddb7aa7364535aeb02,
title = "Fibroblast growth factor 2 and the protease activity of tumor",
abstract = "In BK virus (BKV)/tat transgenic mice, the relatively low incidence and long latency period of tumors indicate that the BKV/tat transgene is not sufficient for the expression of a complete oncogenic phenotype. Since angiogenesis and the production of proteases are critical for tumor growth, we evaluated the expression of two potent angiogenic molecules, fibroblast growth factor type 2 (FGF-2), and hepatocyte growth factor (HGF), and of the fibrinolytic system in cell lines isolated from tumors of different histotypes developed by BKV/tat transgenic mice. Here we show that the overexpression of HGF is a unique feature of spindle cells derived from murine Kaposi's sarcoma-like lesions, whereas FGF-2 is detectable in all the cell lines tested. Interestingly, FGF-2 is secreted only by adenocarcinoma-derived T53 cells that show a fully transformed phenotype in vitro. In addition, T53 cells synthesize larger amounts of urokinase-type plasminogen activator (uPA) than the other cell lines studied. This is due to the secretion of FGF-2 and not to the presence of extracellular Tat. We conclude that the high levels of expression of uPA and its receptor, and the very low levels of plasminogen activator inhibitor type 1, may contribute to the tumorigenic phenotype of T53 cells.",
author = "Maier, {J. A M} and M. Mariotti and L. Meneghini and U. Cavallaro and Z. Wu and G. Massazza and D. Campioni and a. Corallini and G. Barbanti-Brodano and Soria, {M. R.}",
year = "1996",
doi = "10.1016/S0268-9499(96)80012-9",
language = "English",
volume = "10",
pages = "309--315",
journal = "Fibrinolysis and Proteolysis",
issn = "1369-0191",
publisher = "Churchill Livingstone",
number = "5-6",

}

TY - JOUR

T1 - Fibroblast growth factor 2 and the protease activity of tumor

AU - Maier, J. A M

AU - Mariotti, M.

AU - Meneghini, L.

AU - Cavallaro, U.

AU - Wu, Z.

AU - Massazza, G.

AU - Campioni, D.

AU - Corallini, a.

AU - Barbanti-Brodano, G.

AU - Soria, M. R.

PY - 1996

Y1 - 1996

N2 - In BK virus (BKV)/tat transgenic mice, the relatively low incidence and long latency period of tumors indicate that the BKV/tat transgene is not sufficient for the expression of a complete oncogenic phenotype. Since angiogenesis and the production of proteases are critical for tumor growth, we evaluated the expression of two potent angiogenic molecules, fibroblast growth factor type 2 (FGF-2), and hepatocyte growth factor (HGF), and of the fibrinolytic system in cell lines isolated from tumors of different histotypes developed by BKV/tat transgenic mice. Here we show that the overexpression of HGF is a unique feature of spindle cells derived from murine Kaposi's sarcoma-like lesions, whereas FGF-2 is detectable in all the cell lines tested. Interestingly, FGF-2 is secreted only by adenocarcinoma-derived T53 cells that show a fully transformed phenotype in vitro. In addition, T53 cells synthesize larger amounts of urokinase-type plasminogen activator (uPA) than the other cell lines studied. This is due to the secretion of FGF-2 and not to the presence of extracellular Tat. We conclude that the high levels of expression of uPA and its receptor, and the very low levels of plasminogen activator inhibitor type 1, may contribute to the tumorigenic phenotype of T53 cells.

AB - In BK virus (BKV)/tat transgenic mice, the relatively low incidence and long latency period of tumors indicate that the BKV/tat transgene is not sufficient for the expression of a complete oncogenic phenotype. Since angiogenesis and the production of proteases are critical for tumor growth, we evaluated the expression of two potent angiogenic molecules, fibroblast growth factor type 2 (FGF-2), and hepatocyte growth factor (HGF), and of the fibrinolytic system in cell lines isolated from tumors of different histotypes developed by BKV/tat transgenic mice. Here we show that the overexpression of HGF is a unique feature of spindle cells derived from murine Kaposi's sarcoma-like lesions, whereas FGF-2 is detectable in all the cell lines tested. Interestingly, FGF-2 is secreted only by adenocarcinoma-derived T53 cells that show a fully transformed phenotype in vitro. In addition, T53 cells synthesize larger amounts of urokinase-type plasminogen activator (uPA) than the other cell lines studied. This is due to the secretion of FGF-2 and not to the presence of extracellular Tat. We conclude that the high levels of expression of uPA and its receptor, and the very low levels of plasminogen activator inhibitor type 1, may contribute to the tumorigenic phenotype of T53 cells.

UR - http://www.scopus.com/inward/record.url?scp=0030451148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030451148&partnerID=8YFLogxK

U2 - 10.1016/S0268-9499(96)80012-9

DO - 10.1016/S0268-9499(96)80012-9

M3 - Article

AN - SCOPUS:0030451148

VL - 10

SP - 309

EP - 315

JO - Fibrinolysis and Proteolysis

JF - Fibrinolysis and Proteolysis

SN - 1369-0191

IS - 5-6

ER -